Sunday, July 25, 2021

Can peritoneal carcinomatosis of colorectal origin be treated with oral everolimus or in combination with capecitabine? Preliminary results

The mTOR inhibitor everolimus suppressed tumor growth in the mouse model of colon cancer-induced peritoneal carcinomatosis when administered orally or in combination with capecitabine. However, the limitation of this study was the small sample size. Our study is unique because it has investigated whether peritoneal carcinomatosis could be treated with oral chemotherapeutic agents. 

http://www.revistamedicinamilitara.ro/wp-content/uploads/2021/11/1.RJMM-vol-CXXIV-nr-4-din-2021.pdf








Romanian Journal of Military Medicine

http://www.revistamedicinamilitara.ro/

http://www.revistamedicinamilitara.ro/wp-content/uploads/2021/11/1.RJMM-vol-CXXIV-nr-4-din-2021.pdf

No comments: